Midesteine
Alternative Names: MR 889Latest Information Update: 25 Feb 2008
At a glance
- Originator Medea Research
- Developer Medea Research; Pulitzer
- Class Expectorants
- Mechanism of Action Chymotrypsin inhibitors; Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Bronchitis; Cystic fibrosis; Emphysema